Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Tarceva and Capecitabine for Pancreatic Cancer

This study has been completed.
Genentech, Inc.
Roche Global Development
Brigham and Women's Hospital
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Information provided by:
Dana-Farber Cancer Institute Identifier:
First received: July 27, 2005
Last updated: October 30, 2009
Last verified: October 2009
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2008
  Primary Completion Date: June 2004 (Final data collection date for primary outcome measure)